One woman affected by Ireland's cervical cancer scandal has settled with the Irish health service and US-based Quest Diagnostics.
Though the South Carolina Supreme Court said Quest was a healthcare provider, Williams can try to keep her case alive by arguing she's alleging ordinary negligence.
The court's ruling that Quest was acting as a licensed healthcare provider could affect the statute of limitations in the suit.
The prospective analysis suggests that the approach could help clinicians identify patients at risk of a stroke who could benefit from anticoagulant treatment.
The companies are accelerating the pace of an existing collaboration with the goal of detecting SMA "2+0" carrier status.
The 4,000-participant study will use a digital enrollment platform and will provide free genetic testing as well as support from doctors and genetics experts.
The court's determination is critical to deciding if Williams v Quest/Athena can advance or if it must be dismissed on statute of repose grounds.
Sensitivity problems with rapid antigen tests are also helping the more accurate rapid molecular tests gain wider acceptance, manufacturers said.
Changes to Medicare reimbursements are forcing hospitals to create lab-focused joint ventures and partner in various ways with other organizations to stay financially viable.
Quest will also have early access to Thermo Fisher's pipeline of novel platforms and assays to assist with development of Oncomine-branded solutions.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.